Insider · CIK 0001595244
Alan Mateo
director
Files at TXG (10x Genomics, Inc.). First filing Feb 25, 2025, latest Feb 25, 2025.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
1 / 0
$446k bought, $0 sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
TXG: 10x Genomics, Inc.
TXGOct 9, 2026 · close 80.65
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 60Notable | TXGbuy 10x Genomics, Inc. | $446k 40,000 shares | +184% | 0% from low-54% from high |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 3, 2025 | TXG 10x Genomics, Inc. | AGrant or award Class A Common Stock | +15,357 | $0.00 | $0 | 77,048 | Jun 5, 2025 |
| Feb 21, 2025 | TXG 10x Genomics, Inc. | POpen-market purchase Class A Common Stock | +40,000 | $11.14 | $446k | 61,691 | Feb 25, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.